Tag: bacteria

  • IU surgeon-scientist investigates the role of sinus microbiome in chronic rhinosinusitis

    IU surgeon-scientist investigates the role of sinus microbiome in chronic rhinosinusitis

    [ad_1]

    An Indiana University School of Medicine surgeon-scientist is leading a multi-institutional grant investigating the role of the sinus microbiome in chronic rhinosinusitis, an inflammatory disease that causes the lining of the sinuses to swell. The research team will study biospecimens from human sinus surgery patients in the lab and examine how bacteria in the microbiome shape the disease process and might offer novel therapeutic strategies.

    Vijay Ramakrishnan, MD, professor of otolaryngology-;head and neck surgery and a primary member of Stark Neurosciences Research Institute, has spent over a decade investigating the microbiome. The five-year, $2.9 million grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, is a first-of-its-kind grant studying the physiological effect of the sinus microbiome on chronic rhinosinusitis.

    The microbiome is an accumulation of microorganisms-;bacteria, fungi and viruses-;that live within areas of the human body, such as the gut and sinus cavities. These microbes can shape a person’s health, predispose people to disease, act as disease modifiers and influence how people respond to specific treatments. In chronic rhinosinusitis, scientists believe microbes and bacteria play a role in sinus inflammation beyond a person’s traditional sinus infection.

    The upper airway is heavily colonized with bacteria, and the different types of influence immune processes and the general function of the surface lining. If we can steer the microbiome into a favorable healthy state, there are some functions that we can influence to maybe get us better treatment results.”


    Vijay Ramakrishnan, MD, professor of otolaryngology-;head and neck surgery and a primary member of Stark Neurosciences Research Institute

    Ramakrishnan will work with researchers at the University of Colorado School of Medicine, led by Daniel Frank, PhD. Ramakrishnan started his research of the microbiome when he was a faculty member at the University of Colorado; he joined IU School of Medicine in January 2022.

    Chronic rhinosinusitis affects nearly 10% of adults in the United States. Most patients manage the disease medically through sinus rinses, nasal spray medications and allergy treatments. It’s estimated, however, that 15% of chronic rhinosinusitis patients pursue sinus surgery, where most cases result in subpar outcomes, Ramakrishnan said. The volume of chronic rhinosinusitis cases, he added, is expected to rise due to climate change, pollution and western diet.

    Antibiotics have long been prescribed for chronic rhinosinusitis-;it’s one of the top conditions for antibiotic use, according to the Centers for Disease Control and Prevention-;but they haven’t shown to be effective in treating most patients, Ramakrishnan said. The disease is now viewed as inflammatory rather than infectious, creating a need to develop new treatment strategies.

    “This problem is very prevalent in adults. There’s only a handful of therapies, and they work about 75% of the time,” Ramakrishnan said. “Understanding the role of microbiome in this disease and focusing clinical approaches to restrict antibiotic use are our two main health outcomes.”

    Researchers will collect biospecimens of surgical patients to investigate host-microbial processes in airway mucosal immunology. They’ll also use cell cultures to test how various microorganisms impact disease processes and initiate specific immune responses.

    The grant also supports a longitudinal multi-institutional human intervention study of chronic rhinosinusitis surgical patients. The research team will investigate patient outcomes, medication use and how the microbiome of patients changes over time, Ramakrishnan said.

    Ramakrishnan said this study moves beyond prior small observational studies by defining molecular, cellular, and immunological processes using a multi-omics approach, which incorporates data derived from transcriptomics and metabolomics.

    The team will collaborate with Thomas O’Connell, PhD, associate professor of otolaryngology-;head and neck surgery, to conduct tissue metabolomics and with IU network scientists at the Luddy School of Informatics, Computing, and Engineering at IU Bloomington to do a physics-based approach to understand networks of interaction between disease and patient outcomes and tissue-level multi-omics.

    “We’re trying to figure out which chronic rhinosinusitis patients have a microbial component that we can influence, to steer them to better outcomes and allow their own bodies to restore health, thereby limiting antibiotic use and number of interventions,” Ramakrishnan said.

    [ad_2]

    Source link

  • Scientists coax a deadly bacterium to destroy itself from the inside out

    Scientists coax a deadly bacterium to destroy itself from the inside out

    [ad_1]

    Northwestern University researchers have successfully coaxed a deadly pathogen to destroy itself from the inside out.

    In the new study, researchers modified DNA from a bacteriophage or “phage,” a type of virus that infects and replicates inside of bacteria. Then, the research team put the DNA inside Pseudomonas aeruginosa (P. aeruginosa), a deadly bacterium that is also highly resistant to antibiotics. Once inside the bacterium, the DNA bypassed the pathogen’s defense mechanisms to assemble into virions, which sliced through the bacterium’s cell to kill it.

    Building on a growing interest in “phage therapies,” the experimental work represents a critical step toward engineering designer viruses as new therapeutics to kill antibiotic-resistant bacteria. It also reveals vital information about the innerworkings of phages, a little-studied area of biology.

    The study will be published on Wednesday (Jan. 24) in the journal Microbiology Spectrum.

    “Antimicrobial resistance is sometimes referred to as the ‘silent pandemic,’” said Northwestern’s Erica Hartmann, who led the work. “The numbers of infections and deaths from infections are increasing worldwide. It’s a massive problem. Phage therapy has emerged as an untapped alternative to our reliance on using antimicrobials. But, in many ways, phages are microbiology’s ‘final frontier.’ We don’t know much about them. The more we can learn about how phage work, the more likely we can engineer more effective therapeutics. Our project is cutting-edge in that we are learning about phage biology in real time as we engineer them.”

    An indoor microbiologist, Hartmann is an associate professor of civil and environmental engineering at Northwestern’s McCormick School of Engineering and a member of the Center for Synthetic Biology.

    Desperate need for antibiotic alternatives

    Associated with an increase in antimicrobial use, the rise of antibacterial resistance is an urgent and growing threat to the global population. According to the Centers for Disease Control and Prevention (CDC), nearly 3 million antimicrobial-resistant infections occur each year in the United States alone, with more than 35,000 people dying as a result.

    The growing crisis has motivated researchers to look for alternatives to antibiotics, which are continually losing effectiveness. In recent years, researchers have started to explore phage therapies. But even though billions of phages exist, scientists know very little about them.

    For every bacterium that exists, there are dozens of phages. So, there is an astronomically large number of phages on Earth, but we only understand a handful of them. We haven’t necessarily had the motivation to really study them. Now, the motivation is there, and we are increasing the number of tools we have to dedicate to their study.”


    Erica Hartmann, Northwestern University

    Treatment without side effects

    To explore potential phage therapies, researchers either pinpoint or modify an existing virus to selectively target a bacterial infection without disrupting the rest of body. Ideally, scientists one day could tailor a phage therapeutic to infect a specific bacterium and design “a la carte” therapeutics with precise traits and characteristics to treat individual infections.

    “What’s powerful about phage is it can be very specific in the way that antibiotics are not,” Hartmann said. “If you take an antibiotic for a sinus infection, for example, it disrupts your entire gastrointestinal tract. A phage therapy can be designed to affect only the infection.”

    While other researchers have investigated phages therapies, almost all of those studied have focused on using phages to infect Escherichia coli. Hartmann, however, decided to focus on P. aeruginosa, one of the five most deadly human pathogens. Particularly dangerous for people with compromised immune systems, P. aeruginosa is a leading cause of hospital infections, often infecting patients with burn or surgery wounds as well as lungs in people with cystic fibrosis.

    “It is one of the highest priority, multi-drug resistant pathogens that many people are really concerned about,” Hartmann said. “It is extremely drug resistant, so there is an urgent need to develop alternative therapeutics for it.”

    Mimicking infection, bypassing defenses

    In the study, Hartmann and her team started with P. aeruginosa bacteria and purified DNA from several phages. Then, they used electroporation -; a technique that delivers short, high-voltage pulses of electricity -; to poke temporary holes in the bacteria’s outer cell. Through these holes, phage DNA entered the bacteria to mimic the process of infection.

    In some cases, the bacteria recognized the DNA as a foreign object and shredded the DNA to protect itself. But after using synthetic biology to optimize the process, Hartmann’s team was able to knock out the bacteria’s antiviral self-defense mechanisms. In these cases, the DNA successfully carried information into the cell, resulting in virions that killed the bacteria.

    “Where we were successful, you can see dark spots on the bacteria,” Hartmann said. “This is where the viruses burst out of the cells and killed all the bacteria.”

    After this success, Hartmann’s team introduced DNA from two more phages that are naturally unable to infect their strain of P. aeruginosa. Yet again, the process worked.

    Phage manufacturing in a cell

    Not only did the phage kill the bacteria, the bacteria also ejected billions more phages. These phages can then be used to kill other bacteria, like those causing an infection.

    Next, Hartmann plans to continue modifying phage DNA to optimize potential therapies. For now, her team is studying the phages expelled from the P. aeruginosa.

    “This is an important piece in making phage therapies,” she said. “We can study our phage in order to decide which ones to develop and eventually mass produce them as a therapeutic.”

    The study, “A synthetic biology approach to assemble and reboot clinically relevant Pseudomonas aeruginosa tailed phages,” was supported by the Walder Foundation, the National Science Foundation and the National Institutes of Health.

    Source:

    Journal reference:

    Ipoutcha, T., et al. (2024) A synthetic biology approach to assemble and reboot clinically relevant Pseudomonas aeruginosa tailed phages. Microbiology Spectrum. doi.org/10.1128/spectrum.02897-23.

    [ad_2]

    Source link

  • The unlikely extremophiles lurking in your kitchen

    The unlikely extremophiles lurking in your kitchen

    [ad_1]

    New Scientist Default Image

    “CAN I ask what all this is for?” The pharmacy assistant is eyeing me suspiciously. I have just asked for some covid tests, urine sample pots and sterile scalpel blades. Oh, and some latex gloves, please. “I want to see if there are extreme life forms hiding in my dishwasher,” I explain. “I see,” she says carefully, before scurrying off to consult a colleague.

    It is an unusual shopping list, I’ll admit. To explain it, I need to rewind to June, when I spotted a study about bacteria that can live in what humans consider to be extreme conditions, such as high temperatures, caustic liquids or intense radiation. Normally, scientists head to exotic locations to find these microbes, such as the scalding volcanic springs of Yellowstone National Park or the frozen deserts of Antarctica. But you don’t have to go to the ends of the earth to find them, this study said. Chances are, extreme-loving microbes are not only surviving, but thriving, in the appliances in your kitchen.

    That was it. I had to find out whether my kitchen really was home to microbes whose adaptations are like a list of superhero powers. In the process, I gained a new appreciation of the diversity of life – and won’t see my coffee machine in quite the same way again.

    Extreme-loving microbes are a goldmine for bioprospectors who pan the natural world for biotechnology innovations. Covid PCR tests, for example, rely on a DNA-copying enzyme first isolated from a bacterium called Thermus aquaticus that lives in hot springs, tolerating temperatures hot enough to poach an egg.

    [ad_2]

    Source link